JP2002516900A5 - - Google Patents

Download PDF

Info

Publication number
JP2002516900A5
JP2002516900A5 JP2000552085A JP2000552085A JP2002516900A5 JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5 JP 2000552085 A JP2000552085 A JP 2000552085A JP 2000552085 A JP2000552085 A JP 2000552085A JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5
Authority
JP
Japan
Prior art keywords
compound
solvate
pharmaceutically acceptable
preparing
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000552085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516900A (ja
JP3554539B2 (ja
Filing date
Publication date
Priority claimed from SE9801992A external-priority patent/SE9801992D0/xx
Application filed filed Critical
Publication of JP2002516900A publication Critical patent/JP2002516900A/ja
Application granted granted Critical
Publication of JP3554539B2 publication Critical patent/JP3554539B2/ja
Publication of JP2002516900A5 publication Critical patent/JP2002516900A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000552085A 1998-06-04 1999-05-31 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉ Expired - Fee Related JP3554539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801992A SE9801992D0 (sv) 1998-06-04 1998-06-04 New 3-aryl-2-hydroxypropionic acid derivative I
SE9801992-0 1998-06-04
PCT/SE1999/000941 WO1999062872A1 (en) 1998-06-04 1999-05-31 New 3-aryl-2-hydroxypropionic acid derivative (i)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003273428A Division JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Publications (3)

Publication Number Publication Date
JP2002516900A JP2002516900A (ja) 2002-06-11
JP3554539B2 JP3554539B2 (ja) 2004-08-18
JP2002516900A5 true JP2002516900A5 (enExample) 2005-04-28

Family

ID=20411587

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000552085A Expired - Fee Related JP3554539B2 (ja) 1998-06-04 1999-05-31 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉ
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Country Status (39)

Country Link
US (5) US6258850B1 (enExample)
EP (1) EP1084103B1 (enExample)
JP (2) JP3554539B2 (enExample)
KR (1) KR100625152B1 (enExample)
CN (2) CN1310881C (enExample)
AR (2) AR020875A1 (enExample)
AT (1) ATE246674T1 (enExample)
AU (1) AU752261B2 (enExample)
BR (1) BR9910928A (enExample)
CA (1) CA2333938C (enExample)
CZ (1) CZ297424B6 (enExample)
DE (1) DE69910203T2 (enExample)
DK (1) DK1084103T3 (enExample)
DZ (1) DZ2800A1 (enExample)
EE (1) EE04772B1 (enExample)
EG (1) EG24140A (enExample)
ES (1) ES2205844T3 (enExample)
HR (1) HRP20000782B1 (enExample)
HU (1) HUP0103376A3 (enExample)
ID (1) ID28833A (enExample)
IL (1) IL139636A (enExample)
IS (1) IS2071B (enExample)
MA (1) MA26635A1 (enExample)
MY (1) MY117785A (enExample)
NO (1) NO323426B1 (enExample)
NZ (1) NZ508452A (enExample)
PL (1) PL195189B1 (enExample)
PT (1) PT1084103E (enExample)
RS (1) RS49688B (enExample)
RU (1) RU2214999C2 (enExample)
SA (1) SA99200304B1 (enExample)
SE (1) SE9801992D0 (enExample)
SK (1) SK284642B6 (enExample)
TN (1) TNSN99108A1 (enExample)
TR (1) TR200003581T2 (enExample)
TW (1) TW446696B (enExample)
UA (1) UA71912C2 (enExample)
WO (1) WO1999062872A1 (enExample)
ZA (1) ZA200006774B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
DE69831673C5 (de) 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6130214A (en) * 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US7084177B2 (en) 1999-12-03 2006-08-01 Astrazeneca Ab Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
TW574193B (en) * 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
AU773777B2 (en) 1999-12-03 2004-06-03 Astrazeneca Ab Crystalline form of (S)-2 ethoxy-3-(4-(2-(4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
SE9904415D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New process
SE9904421D0 (sv) 1999-12-03 1999-12-03 Astra Ab New compounds
ATE275967T1 (de) * 2000-01-10 2004-10-15 Amylin Pharmaceuticals Inc Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
US6559335B2 (en) 2000-09-22 2003-05-06 Dr. Reddy's Laboratories Limited Process for the preparation of 3-aryl-2-hydroxy propanoic acid
DE60123665T2 (de) 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
US20050014955A1 (en) * 2001-06-01 2005-01-20 Robert Ehrl Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
EA200400010A1 (ru) 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов активаторов пролиферации пероксисом
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
UA82835C2 (en) 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
SE0201005D0 (sv) * 2002-04-02 2002-04-02 Astrazeneca Ab New Process
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
CA2489834C (en) * 2002-06-20 2006-10-03 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201936D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US7351858B2 (en) * 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20060015640A (ko) * 2003-06-06 2006-02-17 카딜라 헬스케어 리미티드 분리 없이 3-아릴-2-하이드록시 프로파노익산 유도체를제조하는 방법
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
JP2007512222A (ja) * 2003-11-27 2007-05-17 高砂香料工業株式会社 光学活性３−（４−ヒドロキシフェニル）プロピオン酸類の製造方法
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
CA2560417C (en) 2004-04-03 2011-04-19 Astrazeneca Ab 1,2-diarylimidazole-4-carboxamide derivatives
FR2872159B1 (fr) * 2004-06-28 2007-10-05 Merck Sante Soc Par Actions Si Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CN102600144A (zh) * 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
GB2454615A (en) * 2006-07-21 2009-05-13 Lupin Ltd Antidiabetic azabicyclo (3.1.0) hexan compounds
KR100958831B1 (ko) * 2006-09-19 2010-05-24 주식회사유한양행 헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
US20090082441A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched tesaglitazar
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
LT3400944T (lt) 2010-11-04 2020-09-25 Albireo Ab Ibat inhibitoriai, skirt kepenų ligų gydymui
BR112013010705B1 (pt) 2010-11-08 2020-11-17 Albireo Ab uso de um inibidor de ibat e um coagulante de ácido biliar, e formulação farmacêutica
EP2758041B1 (de) 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
DK2978748T3 (en) * 2013-03-27 2017-07-24 Pfizer Ireland Pharmaceuticals Process and intermediates for the preparation of pregabalin
CN105764884B (zh) * 2013-07-22 2019-01-18 新陈代谢解决方案开发公司 用于治疗代谢疾病的ppar-节制性化合物
JP2025538159A (ja) 2022-11-08 2025-11-26 ジェンフィット 肝不全の治療において使用するためのｐｐａｒ－アルファ／ガンマアゴニスト

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4114417A (en) * 1977-06-27 1978-09-19 Schmelzer Corporation Method and apparatus for making metal parts
US4479005A (en) * 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
FR2653119B1 (fr) 1989-10-18 1994-08-05 Lipha Nouveaux aryloxy alcoyl benzenes, leurs procedes de preparation et les compositions pharmaceutiques en renfermant.
US5068345A (en) * 1989-10-30 1991-11-26 Eastman Kodak Company Oxazolidinone aldol adduct
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0648212B1 (en) * 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DK0916651T3 (da) * 1996-04-04 2003-12-01 Sankyo Co Phenylalkylcarboxylsyrederivater
CA2307820C (en) * 1997-10-27 2007-04-24 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I

Similar Documents

Publication Publication Date Title
JP2002516900A5 (enExample)
RU2214999C2 (ru) Производное 3-арил-2-гидроксипропионовой кислоты, способ его получения(варианты), фармацевтический препарат, способ лечения и промежуточный продукт
RU2000130189A (ru) Новое производное i 3-арил-2-гидроксипропионовой кислоты
EP0668851B1 (en) A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent
JP2002508375A5 (enExample)
CA2432121A1 (en) Nitric oxide synthase inhibitor phosphate salt
HK1006306B (en) A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent
TW200920374A (en) Rosuvastatin calcium in solid state, pharmaceutical composition comprising the same, and use thereof
JP2002513793A5 (enExample)
JP2005513014A5 (enExample)
US6939856B2 (en) Method for preparing dexchlor tannate
HUP0100500A2 (hu) Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrátja, eljárás az előállításukra és gyógyászati alkalmazása
KR20040020926A (ko) 중수소화된 엔-치환 및 α-치환 디페닐알콕시 아세트산아미노 알킬 에스테르 및 이 화합물을 포함한 의약품
CA1172170A (en) Antiviral alpha, alpha-dialkyl adamantylethylamines
US6329407B1 (en) Use of polycyclic thiazole systems for the treatment of obesity
RU2005109560A (ru) Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина
JPH0725724B2 (ja) トラネキサム酸亜鉛化合物
KR100601244B1 (ko) 티아졸리딘디온 유도체 및 그의 당뇨병약으로서의 용도
RU2007143025A (ru) Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты
KR100677815B1 (ko) 티아졸리딘디온 유도체 및 그의 당뇨병약으로서의 용도
JP2003519683A5 (enExample)
US6096760A (en) Solid α-phenyl-2-piperidine acetate free base, its preparation and use in medicine
JP2004532265A5 (enExample)
JPH033671B2 (enExample)
JP2003520835A5 (enExample)